Claims
- 1. A method of inhibiting restenosis comprising administering to a subject a pharmaceutically effective dose of a wortmannin analog having the following general chemical formula:
- 2. The method of claim 1, wherein the chemical formula corresponds to:
- 3. The method of claim 1, wherein the chemical formula corresponds to:
- 4. The method of claim 1, wherein the chemical formula corresponds to:
- 5. The method of claim 1, wherein the chemical formula corresponds to:
- 6. The method of claim 1, wherein the chemical formula corresponds to:
- 7. The method of claim 1, wherein the chemical formula corresponds to:
- 8. A stent comprised of a stent body coated with a compound of the following formula:
- 9. The stent of claim 8, wherein the compound has the formula:
- 10. The stent of claim 8, wherein the compound has the formula::
- 11. The stent of claim 8, wherein the compound has the formula::
- 12. The stent of claim 8, wherein the compound has the formula::
- 13. The stent of claim 8, wherein the compound has the formula::
- 14. The stent of claim 8, wherein the compound has the formula::
- 15. The stent of claim 10, wherein the compound is releasable from a sustained release matrix.
- 16. The stent of claim 12, wherein the compound is releasable from a sustained release matrix.
- 17. The stent of claim 14, wherein the compound is releasable from a sustained release matrix.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 60/322,143 filed Sep. 14, 2001, which is hereby incorporated by reference in its entirety herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60322143 |
Sep 2001 |
US |